Top Page
Iperionx Limited
(Sydney:IPX)
Iperionx Limited (IPX) vs. iShares MSCI Australia ETF (EWA)
Iperionx Limited Business Overview & Revenue Model
Iperionx Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -657.16K | -634.11K | -211.58K | -9.38K |
| EBITDA | -37.79K | -37.79M | -22.49M | -17.48M | -29.39M | -8.82M |
| Net Income | -35.35K | -35.35M | -22.23M | -25.93M | -21.52M | -14.43M |
Balance Sheet | ||||||
| Total Assets | 105.03M | 105.03M | 55.44M | 22.80M | 9.91M | 2.79M |
| Cash, Cash Equivalents and Short-Term Investments | 54.81M | 54.81M | 33.16M | 11.94M | 5.67M | 1.70M |
| Total Debt | 3.93M | 3.93M | 1.49M | 975.31K | 543.03K | 475.65K |
| Total Liabilities | 12.59M | 12.59M | 4.10M | 2.24M | 2.49M | 762.50K |
| Stockholders Equity | 92.44M | 92.44M | 51.34M | 20.56M | 7.42M | 1.76M |
Cash Flow | ||||||
| Free Cash Flow | -1.65M | -39.41M | -26.68M | -18.57M | -14.06M | -3.62M |
| Operating Cash Flow | -1.18M | -21.80M | -18.61M | -15.86M | -12.13M | -3.56M |
| Investing Cash Flow | -8.03M | -24.28M | -6.53M | -5.71M | -3.07M | 1.76M |
| Financing Cash Flow | 64.17M | 67.99M | 46.59M | 27.89M | 19.39M | 3.50M |
Iperionx Limited Technical Analysis
Iperionx Limited Risk Analysis
Iperionx Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$240.76M | -11.89 | -3.24% | 1.54% | 14.64% | -213.25% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
48 Neutral | AU$557.06M | -31.06 | -7.50% | ― | ― | 51.47% | |
46 Neutral | AU$2.41B | -38.78 | -50.19% | ― | ― | -20.85% | |
46 Neutral | AU$164.17M | -26.43 | -8.25% | ― | ― | -55.56% | |
45 Neutral | AU$975.80M | -29.90 | -13.97% | ― | 620.73% | -21.19% | |
44 Neutral | AU$474.29M | -16.20 | -45.39% | ― | ― | -91.89% |
Iperionx Limited Corporate Events
IperionX Limited has received the final US$4.6 million tranche of a US$47.1 million award from the U.S. Department of War’s Industrial Base Analysis and Sustainment program, funding the scale-up of titanium production and advanced manufacturing at its Virginia Titanium Manufacturing Campus to a planned capacity of 1,400 metric tons per year. In a further boost to its supply chain position, the U.S. Government has also transferred about 290 metric tons of high-quality Ti64 titanium scrap to the company at no cost—equivalent to roughly 1.5 years of feedstock at current full operating capacity—underscoring federal efforts to build a resilient, low-cost domestic titanium platform and reducing IperionX’s reliance on imported material while supporting its role in the U.S. defense industrial base.
The most recent analyst rating on (AU:IPX) stock is a Hold with a A$7.50 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited announced that all remaining vendor performance-linked securities issued in connection with its 2020 acquisition of the Titan Critical Minerals Project in Tennessee have expired, including 19.8 million Class B Performance Shares and a total of 8 million performance options across two classes. Following this expiry, the company detailed an updated capital structure comprising 336.3 million quoted ordinary shares and a suite of unquoted employee performance rights, restricted stock units and options with various strike prices and maturities, clarifying its current equity overhang for investors and simplifying its capital base after contingent vendor instruments have lapsed.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has reported a change in the securities held by director Todd Hannigan, detailing adjustments to his direct and indirect interests in the company’s shares and equity instruments. The filing shows the lapse of 1,260,000 unlisted Class B performance shares and 560,000 A$0.20 performance options, which converted into a single fully paid ordinary share, leaving Hannigan with an increased total of 25,243,776 ordinary shares while his performance share and option holdings were removed; the change was recorded as having no consideration and did not involve trading during a closed period, signalling an internal restructuring of his incentive-based holdings rather than a market transaction.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has issued 678,429 fully paid ordinary shares, which form part of its existing quoted class on the Australian Securities Exchange. The company confirmed that the issuance was conducted without a prospectus under the relevant exemptions of the Corporations Act, and stated it remains in compliance with its financial reporting and continuous disclosure obligations, with no excluded information that would need to be disclosed to investors at this time.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
Iperionx Limited has applied to the ASX for quotation of 678,429 new fully paid ordinary shares under its IPX ticker, following the conversion or exercise of existing options or other convertible securities. The modest increase in quoted share capital reflects ongoing capital management activity but does not, on the information provided, signal a major change in strategy or operations; it slightly expands the company’s free float and may marginally affect existing shareholders’ dilution and trading liquidity.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has notified the market of the issuance of new unquoted equity securities under its employee incentive scheme, including 59,000 performance rights expiring on 31 December 2025, 5,000 performance rights expiring on 31 December 2026, and 235,000 options expiring on 1 April 2027 with an exercise price of A$10.00. The securities are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, highlighting the company’s continued use of equity-based incentives to align staff interests with shareholders and potentially expanding its fully diluted capital base over time.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
Iperionx Limited has notified the market that it is issuing 130,875 unquoted restricted stock units (RSUs) under the ASX code IPXAP on 23 December 2025. The new equity issuance, disclosed via an Appendix 3G filing, modestly increases the company’s pool of unquoted securities and may be related to incentive or compensation arrangements, signalling continued use of equity-based instruments to support capital management and staff or executive alignment with shareholder interests.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has achieved ISO 9001 certification for its titanium manufacturing operations in Virginia, a significant milestone that validates the quality management processes as the company scales production. This certification is crucial for customer qualification and procurement across various sectors, including defense, aerospace, and automotive, and is expected to enhance the company’s operational integrity and secure long-term supply contracts.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has partnered with Carver Pump Company to expedite the production of critical titanium components for U.S. Navy ships. This collaboration aims to address supply chain constraints by reducing lead times for titanium parts from over a year to less than a week, utilizing IperionX’s low-cost titanium metal powder and advanced manufacturing capabilities. The successful prototyping and testing phase could lead to larger production agreements, enhancing naval shipbuilding and maintenance efficiency, and improving fleet readiness.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.90 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
Iperionx Limited has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of November 20, 2025. This change involves various transactions and securities lending agreements managed by JPMorgan’s subsidiaries, which affected a significant number of ordinary shares. The cessation of JPMorgan’s substantial holding status may impact Iperionx’s shareholder structure and market perception, potentially influencing future investor relations and stock performance.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.25 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has released its 2025 Sustainability Report, highlighting its commitment to environmentally friendly practices in titanium alloy production. The report underscores the company’s focus on reducing carbon emissions and energy use, emphasizing its role in advancing sustainable technologies within the industry. This initiative is expected to enhance IperionX’s market position and appeal to stakeholders interested in sustainable and cost-effective titanium solutions.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.25 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has responded to a short seller report by Spruce Point Capital, emphasizing its commitment to confidentiality and data security, and highlighting its focus on scaling up titanium production in Virginia. The company has received significant support and validation from various U.S. Government programs, including a U.S. Army SBIR Phase III contract, reflecting the strategic importance of its technology for the U.S. titanium supply chain. IperionX is advancing its Virginia operations to significantly increase titanium production capacity, supported by U.S. Department of War funding, and is actively working on delivering high-performance titanium solutions for the U.S. military.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.25 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has requested a trading halt on its securities pending an announcement related to a report by Spruce Point Management. The company is preparing a response to this report, following a request from the Australian Securities Exchange (ASX), and the halt will remain until the announcement is made or trading resumes on November 17, 2025.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.25 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has reported significant progress in its operations for the quarter ending September 2025, with all major manufacturing equipment now operational at its Virginia facility, leading to a 60% increase in titanium powder production capacity without additional capital expenditure. The company is scaling up its titanium production capacity to 1,400 tpa by mid-2027, supported by a U.S. Department of War grant, positioning itself as the largest and lowest-cost titanium powder producer in the U.S., which is expected to enhance national security and reduce foreign dependency.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.25 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.
IperionX Limited has announced its Annual General Meeting (AGM) scheduled for November 28, 2025, in Perth, Australia. The company will not send physical copies of the meeting notice unless specifically requested by shareholders, emphasizing a shift towards digital communications. This move aligns with modern corporate governance practices and reflects IperionX’s commitment to sustainability and efficiency. Shareholders are encouraged to review meeting materials online and update their communication preferences to receive electronic updates, ensuring they remain informed and engaged with company developments.
The most recent analyst rating on (AU:IPX) stock is a Buy with a A$9.25 price target. To see the full list of analyst forecasts on Iperionx Limited stock, see the AU:IPX Stock Forecast page.